2 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.91)
-
Publication number: 20110183925Abstract: Provided is an anti-inflammatory composition which has a high efficacy, causes no concern about side effects, is easy to ingest, and can also be administered for a long period of time because of its low cost and high safety. The present invention relates to a peptide comprising an amino acid sequence represented by pyroGlu-(X)n-A or a salt thereof, wherein X is independently Gln, Asn, or Pro; A represents Gln, Asn, Leu, Ile, Met, Val, or Phe; and n represents an integer of 0 to 2, and an anti-inflammatory composition comprising the same.Type: ApplicationFiled: September 22, 2008Publication date: July 28, 2011Applicant: NISSHIN PHARMA INC.Inventors: Kenji Sato, Shin Ono, Yoshio Suzuki
-
Publication number: 20110177140Abstract: This invention relates to the use of 4-amidino benzylamine derivatives as cosmetic ingredients and to cosmetic compositions, as well as to non-therapeutic methods for the cosmetic treatment of the skin and the scalp. Said derivatives and compositions can be used as urokinase inhibitors to prevent and restore damage of the epidermal barrier. Barrier abnormalities and disruptions respectively are often the starting point of a dry skin state, of itching, of dandruff and of the perception of sensitive skin. These 4-amidino benzylamine derivatives can be used for topical skin and scalp care applications in form of creams, lotions, gels, shampoos and the like.Type: ApplicationFiled: August 31, 2007Publication date: July 21, 2011Inventors: Rainer Voegeli, Hugo Ziegler, Mathias Gempeler
-
Publication number: 20110177000Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethylnitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).Type: ApplicationFiled: March 28, 2011Publication date: July 21, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Benjamin M. Gaston, David Gozal
-
Publication number: 20110171171Abstract: A compound of Formula 1.1A: 1.1A or salt thereof, as well as methods of making compounds of Formula 1.1A, methods of using compounds of Formula 1.1A to treat proliferative disorders such as cancer, and related compounds, composition, and methods.Type: ApplicationFiled: June 26, 2009Publication date: July 14, 2011Applicant: Aegera Therapeutics, Inc.Inventors: Alain Laurent, Melanie Proulx, Yannick Rose, James B. Jaquith, Stephen Morris
-
Patent number: 7977315Abstract: Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).Type: GrantFiled: November 16, 2007Date of Patent: July 12, 2011Assignee: Arizona Biomedical Research CommissionInventors: Seth D. Rose, Karl J. Okolotowicz, Rosemarie F. Hartman, Jason Houtchens
-
Publication number: 20110166085Abstract: An edible composition comprising peptides rich in tryptophan, which edible composition further comprises a rapidly available glucose composition and a slowly available glucose composition.Type: ApplicationFiled: April 9, 2009Publication date: July 7, 2011Inventors: Rudolf Beck-hoven Van, Alexander Duchateau, Luppo Edens, Franciscus Kleinherenbrink, Joris Kloek, Andre L. Ross De
-
Patent number: 7973011Abstract: Methods are provided for enhancing myelination. Myelination is enhanced by administration of agents that are inhibitors of ?-secretase. Methods of screening for pharmaceutically active compounds that enhance myelination, and for genes involved in myelination are also provided.Type: GrantFiled: February 13, 2007Date of Patent: July 5, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Trent Alan Watkins, Ben A. Barres
-
Publication number: 20110152175Abstract: The invention provides dendrimeric compounds of the formula 1 comprising amino acids, wherein n is an integer of 1-4, T is an alkylidene —(CH2)2CONH(CH2)2- group, R2 is an —NH2 group or a moiety of a primary organic amine, and P is an amino acid and/or peptide moiety, wherein at least one hydrogen atom of at least one amino group is optionally replaced by a protective group, and a hyperbranched core compound of the formula 3, wherein T and R2 are as defined above. The invention provides also a process for the preparation of a dendrimeric compound and a hyperbranched core, wherein the process employs addition reactions of alkyl acrylate and a basic amino acid, and use of a hyperbranched core for the preparation of a dendrimeric compound comprising amino acids. The invention provides also use of dendrimeric compounds for the preparation of the medicament for inhibiting growth of bacterial cells, fungi and tumor cells.Type: ApplicationFiled: September 18, 2009Publication date: June 23, 2011Applicant: Instytut Chemii Organicznej Polska Akademia NaukInventors: Zofia Lipkowska, Piotr Polcyn, Andrzej Wojciech Lipkowski
-
Publication number: 20110144565Abstract: The invention relates to a combination including at least one bioflavonoid, in particular tiliroside, and at least one peptide, in particular palmitoyl Lysine-Valine-5 diaminohydroxybutyrate. The invention also relates to a cosmetic or dermatological composition containing said combination.Type: ApplicationFiled: June 18, 2009Publication date: June 16, 2011Applicant: LABORATOIRES CLARINSInventor: Olivier Courtin
-
Patent number: 7960350Abstract: Embodiments of the invention disclosed herein relate to methods of preventing and/or ameliorating one or more symptoms associated with an eye disease such as dry eye syndrome, cataracts of the eye and nuclear sclerosis of the eye lens by administering to a subject a therapeutically effective amount of N?-acetyl-L-histidine. Additionally, provided herein are pharmaceutical compositions comprising N?-acetyl-L-histidine. Kits for preventing and/or ameliorating one or more symptoms associated with an eye disease by administering a pharmaceutical composition comprising N?-acetyl-L-histidine are also disclosed.Type: GrantFiled: October 21, 2004Date of Patent: June 14, 2011Assignee: ADER Enterprises, Inc.Inventor: Emilio Robledo
-
Cytoprotective therapeutic agents for the prevention of reperfusion injury following ischemic stroke
Patent number: 7956037Abstract: The present invention relates generally to the use of ?-glutamyl antioxidants, particularly ?-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The ?-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na/Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943).Type: GrantFiled: June 30, 2006Date of Patent: June 7, 2011Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Darryl R. Peterson -
Publication number: 20110130350Abstract: The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (II) in a single step reaction.Type: ApplicationFiled: December 7, 2010Publication date: June 2, 2011Applicant: UCB PHARMA GMBHInventors: Jens Riedner, Gavin Dunne
-
Publication number: 20110130349Abstract: The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Inventors: Jesse Chow, Fabian Gusovksy, Lynn Hawkins, Mark Spyvee
-
Publication number: 20110124585Abstract: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.Type: ApplicationFiled: February 7, 2011Publication date: May 26, 2011Inventors: Patrick G. Harran, Xiaodong Wang, Jef K. De Brabander, Lin Li, Ranny Mathew Thomas, Hidetaka Suzuki
-
Publication number: 20110117009Abstract: The present invention relates to a drug polymer conjugate comprising a pharmaceutically active compound and a dendritic polyglycerol, as well as to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell.Type: ApplicationFiled: March 31, 2009Publication date: May 19, 2011Applicants: FREIE UNIVERSITÄT BERLIN, KTB TUMORFORSCHUNGSGESELLSCHAFT MBHInventors: Felix Kratz, Rainer Haag, Marcelo Calderon
-
Publication number: 20110117057Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.Type: ApplicationFiled: December 20, 2010Publication date: May 19, 2011Applicants: SCHERING CORPORATION, DENDREON CORPORATIONInventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry A. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang
-
Publication number: 20110118177Abstract: The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute.Type: ApplicationFiled: June 15, 2009Publication date: May 19, 2011Inventors: Ahmed Sallam, Alexander Steinbüchel
-
Publication number: 20110111021Abstract: The present invention provides a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active ingredient, and a compartment containing an HMG-CoA reductase inhibitor as a pharmacologically active ingredient, wherein one compartment is a prior-release compartment and the other compartment is a delayed-release compartment. The combination preparation of the present invention can deliver a renin inhibitor and an HMG-CoA reductase inhibitor with a time interval at a specific speed, thus reducing undesirable side-effects, improving the drug efficacy and promoting the patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndromes, cardiovascular diseases, renal diseases and the like, as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.Type: ApplicationFiled: February 23, 2009Publication date: May 12, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jaw Woon Son, Jin Wook Kim
-
Publication number: 20110105417Abstract: Conjugated compounds comprising a therapeutic or diagnostic agent linked to a substrate for a cell membrane transporter or receptor by lipophilic linker are provided.Type: ApplicationFiled: June 26, 2009Publication date: May 5, 2011Inventors: Ashim K. Mitra, Swapan Kumar Samanta
-
Publication number: 20110098229Abstract: Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical steroid.Type: ApplicationFiled: October 28, 2009Publication date: April 28, 2011Inventor: Harbhajan S. Paul
-
Publication number: 20110091403Abstract: Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Methods may comprise using compositions comprising oligosaccharide aldonic acids and additional cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.Type: ApplicationFiled: December 23, 2010Publication date: April 21, 2011Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 7928067Abstract: The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula II: and methods of using such compounds to activate cytoprotective kinases.Type: GrantFiled: May 14, 2009Date of Patent: April 19, 2011Assignee: Ischemix LLCInventors: Alexander Baguisi, Reinier Beeuwkes, Ralph Casale, Steven A. Kates, Alan Lader
-
Publication number: 20110086809Abstract: A method for supporting retinal, intestinal, and/or nervous system development in a neonate is provided. The method involves enterally administering arginine-glutamine dipeptide to a neonate.Type: ApplicationFiled: October 14, 2009Publication date: April 14, 2011Inventors: Joshua Anthony, Kristin Morris, Maria Grant, Joseph Neu
-
Patent number: 7923433Abstract: The present invention provides compositions and methods for assessing profiles of catalytically active enzymes in compositions containing a plurality of proteins. In preferred embodiments, the enzyme is a hydrolase, most preferably a cysteine protease. The methods described herein use activity based probes (“ABPs”) that have an affinity moiety for directing the binding of the ABP to one or more catalytically active target enzymes, a reactive group for forming a covalent bond at an active site of the target enzyme(s), and a TAG (e.g., a detectable label, preferably a fluorophore). One or more ABPs may be combined with a protein-containing sample under conditions for binding and reaction of the ABP(s) with target enzyme(s) that are present in the sample. The resulting products may then be used to assess the active enzyme profile of the sample, and can be correlated to the presence, amount, or activity of one or more target enzyme(s) present in the original complex protein mixture.Type: GrantFiled: October 8, 2003Date of Patent: April 12, 2011Assignee: Activx Biosciences, Inc.Inventors: David Winn, David Alan Campbell
-
Publication number: 20110082087Abstract: The present invention relates to a compound of formula (I) wherein X is hydrogen, R1, R1C(O), R1CO2, or a COX2 inhibitor, wherein R1 is C1-20 alkyl, aryl, arylalkyl, alkyloxy or arylalkyloxy; wherein Y is OR2, NHR3N(R3)2, or a COX inhibitor; wherein R2 is hydrogen or C1-20 alkyl and each R3 is independently hydrogen or a C1-4 alkyl; wherein T is OR4, NHR5N(R5)2, or a COX inhibitor wherein R4 is hydrogen or C1-20 alkyl and each R5 is independently hydrogen or a C1-4 alkyl; wherein Z is hydrogen, R6, R6C(O), R6CO2, or a COX2 inhibitor; wherein R6 is C1-20 alkyl, aryl, arylalkyl, alkyloxy or arylalkyloxy; with the proviso wherein when X and Z are hydrogen and T is OH, Y is not OH; for use in the prevention and/or treatment of pain wherein said compound is provided for systemic administration.Type: ApplicationFiled: April 1, 2009Publication date: April 7, 2011Applicant: Edificio ICATInventors: Marta Maria Batista Ribeiro, Miguel Augusto Rico Botas Castanho, Christophe Francois Aime Roca, Helena Margarida Moreira de Oliveira Vieira, Jose Manuel Bernardo de Sousa, Marta Isabel Heitor Cerejo, Patricia Ramalhete Mendes da Silva Calado, Sukalyan Chatterjee, Eduard Bardaji Rodriguez, Montserrat Heras Corominas, Isaura Ferreira Tavares, Marta Sofia Carvalho Teixeira Pinto, Ana Dulce Ascensao Correia, Manuel Nuno de Sousa Simoes de Mel
-
Publication number: 20110071084Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: ApplicationFiled: June 26, 2008Publication date: March 24, 2011Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Publication number: 20110071093Abstract: Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.Type: ApplicationFiled: March 12, 2009Publication date: March 24, 2011Applicant: Nektar TherapeuticsInventor: Franco J. Duarte
-
Publication number: 20110070270Abstract: An immunostimulating agent, which can stimulate immunity effectively, is described. The immunostimulating agent contains an active ingredient including a calcium receptor activator such as ?-Glu-X-Gly [wherein X represents an amino acid or a derivative thereof other than Cys], ?-Glu-Val-Y [wherein Y represents an amino acid or a derivative thereof], ?-Glu-Ala, ?-Glu-Gly, ?-Glu-Met, ?-Glu-Thr, ?-Glu-Val, ?-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, ?-Glu-Met(O), ?-Glu-?-Glu-Val, ?-Glu-Val-NH2, ?-Glu-Val-ol, ?-Glu-Ser, ?-Glu-Tau, ?-Glu-Cys(S-Me)(O), ?-Glu-Leu, ?-Glu-Ile, ?-Glu-t-Leu, ?-Glu-Cys(S-Me), a cation having a valency of 2 or more, protamine, polylysine, spermine, spermidine, putrescine, cinacalcet, a cinacalcet analogue compound, and a salt of any one of the aforementioned components.Type: ApplicationFiled: October 6, 2010Publication date: March 24, 2011Inventors: Tomohiro Kodera, Yuzuru Eto, Yoshinori Mine
-
Patent number: 7902327Abstract: Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: GrantFiled: May 22, 2008Date of Patent: March 8, 2011Assignee: New York University School of MedicineInventors: Neville Robert Kallenbach, Anne W. Young, Zhigang Liu, Chunhui Zhou
-
Publication number: 20110053837Abstract: The present invention provides a mineral-peptide chelate comprising a peptide consisting of 2˜18 amino acids and a mineral chelated to the peptide, wherein the peptide can be a hydrolysate obtained by hydrolyzing soybean or other protein materials with proteases, or a product obtained by hydrolyzing soybean or other protein material with proteases and fermentation. The mineral-peptide chelate of the present invention may further comprise a carrier which covers the peptide and the mineral which is chelated to the peptide.Type: ApplicationFiled: March 2, 2010Publication date: March 3, 2011Applicant: Nugen Bioscience (Taiwan) Co., Ltd.Inventors: Shann-Tzong Jiang, Li-Jung Yin, Hsueh-Ming Tai
-
Publication number: 20110053858Abstract: A novel class of peptide ?-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA2-AA1-CO—NH—(CH2)n—R3. Processes for the synthesis of peptidyl ?-ketoamide derivatives.Type: ApplicationFiled: July 16, 2008Publication date: March 3, 2011Inventors: James C. Powers, Jonathan D. Glass, Asli Ovat, Zhaozhao Li
-
Publication number: 20110045036Abstract: Topical cosmetic use as a whitening active ingredient of at least one peptide, comprising at least one blocked aromatic cycle and having the general formula (I): A-(Xa)m-Xc-(Xb)n-B. The invention also discloses a cosmetic composition comprising at least said peptide and a method of decreasing skin pigmentation, whitening or lightening human skin, comprising a topical application of said composition.Type: ApplicationFiled: May 4, 2007Publication date: February 24, 2011Applicant: SEDERMAInventors: Karl Lintner, Olivier Peschard
-
Publication number: 20110034397Abstract: Disclosed is an agent, ?-glutamylcysteine, which can effectively and safely stimulate the intestinal immune system. ?-Glutamylcysteine can be formulated in a pharmaceutical composition, a food, and/or a beverage, and used for the treatment or prevention of infectious diseases, diarrhea, polyps, tumors, enteritis or allergy.Type: ApplicationFiled: August 16, 2010Publication date: February 10, 2011Inventors: Tomohiro Kodera, Noriki Nio, Norimasa Onishi, Yoshinori Mine
-
Publication number: 20110033560Abstract: The present invention relates to the use of a preparation comprising a substance that is capable of binding acetaldehyde, and to the use of a filter that is attached to a tobacco product to reduce tobacco and/or alcohol dependence.Type: ApplicationFiled: September 12, 2008Publication date: February 10, 2011Applicant: BIOHIT OYJInventors: Osmo Suovaniemi, Mikko Salaspuro, Ville Salaspuro, Martti Marvola
-
Publication number: 20110033448Abstract: Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.Type: ApplicationFiled: December 17, 2007Publication date: February 10, 2011Inventors: Michel Gilliet, Roberto Lande, Yong-Jun Liu
-
Publication number: 20110015139Abstract: The present disclosure relates to amyloid beta (A?) channels and the diseases and disorders caused by abnormal activity in these channels, such as Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. The disclosure provides compositions and methods that block AO channel activity and/or reduce A?-induced toxicity in a cell. Compositions comprised of compounds having histidine coordinating capacity are used in methods to prevent, reduce, or eliminate damage caused by A? ion channels.Type: ApplicationFiled: March 18, 2009Publication date: January 20, 2011Applicant: he Henry M. JAckson Foundation for the Advancement of Military Medicine, Inc.Inventor: Nelson Arispe
-
Patent number: 7871981Abstract: Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present invention employ peptides such as phosphotyrosyl mimetics. Also disclosed are methods of preventing and/or treating diseases, disorders, states, or conditions such as cancer, particularly metastatic cancer, for example, melanoma or prostate cancer, comprising administering to a mammal of interest one or more peptides of the present invention. Also disclosed are methods of blocking blocks HGF, VEGF, or bFGF-stimulated migration, cell proliferation, and formation of capillary-like structures.Type: GrantFiled: September 22, 2006Date of Patent: January 18, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Donald P Bottaro, Alessio Giubellino, Safiye N Atabey, Jesus V Soriano, Diane E Breckenridge, Terrence R Burke, Jr.
-
Publication number: 20110009346Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.Type: ApplicationFiled: August 10, 2010Publication date: January 13, 2011Inventors: Roger Harris, Mark Dunnett
-
Publication number: 20100323975Abstract: A therapeutic agent for cerebral ischemic injury contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine as an active ingredient. The therapeutic agent for cerebral ischemic injury preferably has a dosage form as an injection for intravenous administration. The therapeutic agent for cerebral ischemic injury having a dosage form as an aqueous injection contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine at a concentration of preferably 0.3 to 3.5 mol/L, and more preferably 0.6 to 2.1 mol/L.Type: ApplicationFiled: December 25, 2008Publication date: December 23, 2010Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Yuichi Kawano, Kazuhisa Doi, Takuya Nii
-
Patent number: 7855181Abstract: The subject invention provides dipeptides useful in promoting healthy muscle tissues as well as effective immune responses. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.Type: GrantFiled: November 10, 2003Date of Patent: December 21, 2010Assignee: University of Florida Research Foundation, Inc.Inventor: Josef Neu
-
Publication number: 20100317601Abstract: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the ?S1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors.Type: ApplicationFiled: July 28, 2010Publication date: December 16, 2010Inventor: ZVI SIDELMAN
-
Publication number: 20100311661Abstract: The present invention relates to the use of certain derivatives of cycloheximide or the pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment or prevention of ischaemias, of cardiopathies, of endothelial disorders, of traumata, of necroses, of pulmonary disorders, of vascular disorders, of forms of shock, of blood flow impairments or of stroke; or for the manufacture of a medicament for the treatment or prevention of diseases caused by ischaemia; or for the manufacture of a composition for the preservation and/or storage of transplants, especially of organs.Type: ApplicationFiled: August 24, 2007Publication date: December 9, 2010Applicant: Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.Inventors: Gerhard Küllertz, Gunter Fischer, Steffi Rau, Britta Erika Husse
-
Patent number: 7846902Abstract: A composition for oral administration is provided, which includes at least one dipeptide represented by the formula: (wherein X represents alanyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property.Type: GrantFiled: September 20, 2006Date of Patent: December 7, 2010Assignee: Kyowa Hakko Bio Co., Ltd.Inventors: Yasushi Sakai, Masao Kimura, Shun Kayahashi, Toshikazu Kamiya, Shin-ichi Hashimoto, Hideo Kawabe
-
Publication number: 20100297182Abstract: An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness.Type: ApplicationFiled: May 20, 2010Publication date: November 25, 2010Inventor: Donna M. Tozzi
-
Publication number: 20100298242Abstract: The invention relates to the use of sweeteners for masking the salty taste of compositions as well as compositions containing salt and defined sweeteners, the amount of sweeteners being suitable for masking the salty taste of the composition.Type: ApplicationFiled: July 26, 2006Publication date: November 25, 2010Inventors: Reiner Postges, Richard Ammer, Joerg Breitkreutz, Dorothee Grueneberg Klinkowski
-
Publication number: 20100297222Abstract: A method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production, is provided.Type: ApplicationFiled: November 6, 2008Publication date: November 25, 2010Applicant: Kaneka CorporationInventors: Kento Kanaya, Masao ` Sato, Akihisa Kanda
-
Publication number: 20100292158Abstract: Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formula Carrier-Linker-Peptide Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.Type: ApplicationFiled: January 15, 2010Publication date: November 18, 2010Inventor: ROBERT H. ZIMMER
-
Publication number: 20100292148Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.Type: ApplicationFiled: August 10, 2007Publication date: November 18, 2010Applicant: STARPHARMA PTY LTD.Inventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
-
Publication number: 20100266677Abstract: The present invention relates to homo- and hetero-dimer compounds formed by a disulfide, sulfinyl thio, or olefin bond between two monomers. A method of making a homo- or hetero-dimer compound is also disclosed. The present invention also relates to monomer compounds capable of forming homo- or hetero-dimer compounds, as well as oligomers formed via linkage of one or more dimers. Also disclosed are methods of inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-I RNA frameshifting stem-loop and a (CUG)n expanded repeat stem-loop are disclosed, as are methods of treating diseases associated with these target RNA molecules. The dimer compounds can also be used for selectively detecting presence of the target RNA molecule in a sample.Type: ApplicationFiled: July 28, 2008Publication date: October 21, 2010Applicant: UNIVERSITY OF ROCHESTERInventors: Benjamin L. Miller, Brian R. McNaughton, Peter C. Gareiss, Joseph Wedekind, Charles Thornton, Krzysztof Sobczak
-
Publication number: 20100260819Abstract: Intraperitoneal administration of glutamine reduces post-operative adhesion formation.Type: ApplicationFiled: August 11, 2006Publication date: October 14, 2010Applicant: University of SaskatchewanInventor: Adebola O.E. Obayan